{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:24:11Z","timestamp":1793211851987,"version":"4.5.0"},"reference-count":204,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":319,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K23AA031310"],"award-info":[{"award-number":["K23AA031310"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Alcohol-associated liver disease (ALD) is a significant global health challenge, encompassing a spectrum from steatotic liver disease to cirrhosis and alcohol-associated hepatitis, and contributed to 25% of global cirrhosis deaths in 2019. The identification of both modifiable (e.g. heavy drinking, metabolic syndromes) and non-modifiable risk factors (e.g. genetic predispositions) is crucial for effective disease management. Alcohol use assessment and treatment, by using both behavioral therapy and pharmacotherapeutic modalities, nutrition support, and optimization of liver disease modifiers, form the cornerstone of management. Advances in medical therapies, such as fecal microbiota transplantation and novel agents such as IL-22, are being explored for their therapeutic potential. A unifying theme in ALD care is the need for a personalized approach to management, accounting for the spectrum of the disease and individual patient characteristics, to tailor interventions effectively. Finally, it is essential to address the challenges to effective ALD treatment, including socioeconomic, logistical, and stigma-related barriers, to improve patient outcomes. This review discusses the current knowledge on ALD, including epidemiology, pathophysiology, risk factors, and management strategies, highlighting the critical role of integrated care models.<\/jats:p>","DOI":"10.1093\/gastro\/goae097","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:09:17Z","timestamp":1730837357000},"source":"Crossref","is-referenced-by-count":7,"title":["Advances in the management of alcohol-associated liver disease"],"prefix":"10.1093","volume":"12","author":[{"given":"Ahmad","family":"Anouti","sequence":"first","affiliation":[{"name":"Division of Digestive and Liver Diseases, UT Southwestern Medical Center , Dallas, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Kerr","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, UT Southwestern Medical Center , Dallas, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack C","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, UT Southwestern Medical Center , Dallas, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G","family":"Cotter","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, UT Southwestern Medical Center , Dallas, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"2024110520090983600_goae097-B1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cld.806","article-title":"Epidemiology of alcohol use and alcoholic liver disease","volume":"13","author":"Mellinger","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2024110520090983600_goae097-B2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2024110520090983600_goae097-B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B4","first-page":"147","article-title":"Alcoholic liver disease: pathogenesis and current management","volume":"38","author":"Osna","year":"2017","journal-title":"Alcohol Res"},{"key":"2024110520090983600_goae097-B5","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/add.13341","article-title":"Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries","volume":"111","author":"Kalinowski","year":"2016","journal-title":"Addiction"},{"key":"2024110520090983600_goae097-B7","author":"NIAAA","year":"2024"},{"key":"2024110520090983600_goae097-B8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale","volume":"170","author":"Hasin","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2024110520090983600_goae097-B9","first-page":"200","article-title":"Alcohol use disorder in alcohol-associated liver disease: two sides of the same coin","volume":"30","author":"Singal","year":"2024","journal-title":"Liver Transpl"},{"key":"2024110520090983600_goae097-B10","first-page":"283","article-title":"Alcohol Consumption: Medical Implications, the Liver and Beyond","volume":"57","author":"Meza","year":"2022","journal-title":"A&A"},{"key":"2024110520090983600_goae097-B11","author":"SAMHSA; Center for Behavioral Health Statistics and Quality","year":"2024"},{"key":"2024110520090983600_goae097-B12","author":"SAMHSA; Center for Behavioral Health Statistics and Quality"},{"key":"2024110520090983600_goae097-B13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/a-2000-6680","article-title":"The changing epidemiology of alcohol-associated liver disease: gender, race, and risk factors","volume":"43","author":"Anouti","year":"2023","journal-title":"Semin Liver Dis"},{"key":"2024110520090983600_goae097-B14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/hep.31539","article-title":"Measuring the alcohol in alcohol-associated liver disease: choices and challenges for clinical research","volume":"73","author":"Mellinger","year":"2021","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.35946\/arcr.v42.1.13","article-title":"Alcohol use disorder and alcohol-associated liver disease","volume":"42","author":"Ramkissoon","year":"2022","journal-title":"Alcohol Res"},{"key":"2024110520090983600_goae097-B16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1186\/s12889-023-15749-x","article-title":"Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis","volume":"23","author":"Niu","year":"2023","journal-title":"BMC Public Health"},{"key":"2024110520090983600_goae097-B17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14218\/JCTH.2021.00227","article-title":"Racial and health disparities among cirrhosis-related hospitalizations in the USA","volume":"10","author":"Singal","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"2024110520090983600_goae097-B18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.22223","article-title":"Racial disparity in liver disease: biological, cultural, or socioeconomic factors","volume":"47","author":"Nguyen","year":"2008","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/acer.12660","article-title":"Ethnic differences in presentation and severity of alcoholic liver disease","volume":"39","author":"Levy","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"2024110520090983600_goae097-B20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cld.2021.03.009","article-title":"Epidemiology of alcohol-associated liver disease","volume":"25","author":"Han","year":"2021","journal-title":"Clin Liver Dis"},{"key":"2024110520090983600_goae097-B21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.clinthera.2023.09.016","article-title":"Multidisciplinary care of alcohol-related liver disease and alcohol use disorder: a narrative review for hepatology and addiction clinicians","volume":"45","author":"Shroff","year":"2023","journal-title":"Clin Ther"},{"key":"2024110520090983600_goae097-B23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B24","doi-asserted-by":"crossref","first-page":"e27087","DOI":"10.1371\/journal.pone.0027087","article-title":"The PNPLA3 rs738409 148M\/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis","volume":"6","author":"Nischalke","year":"2011","journal-title":"PLoS One"},{"key":"2024110520090983600_goae097-B25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/liv.12310","article-title":"PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis","volume":"34","author":"Burza","year":"2014","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B26","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/jgh.12540","article-title":"PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival","volume":"29","author":"Friedrich","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/apt.12890","article-title":"Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis","volume":"40","author":"Chamorro","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2024110520090983600_goae097-B28","doi-asserted-by":"crossref","first-page":"e2234221","DOI":"10.1001\/jamanetworkopen.2022.34221","article-title":"Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024110520090983600_goae097-B29","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B30","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/liv.15322","article-title":"Contribution of a genetic risk score to ethnic differences in fatty liver disease","volume":"42","author":"Kubiliun","year":"2022","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"2024110520090983600_goae097-B32","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.cgh.2020.08.054","article-title":"Interaction between alcohol consumption and PNPLA3 variant in the prevalence of hepatic steatosis in the US population","volume":"19","author":"Lazo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"2024110520090983600_goae097-B34","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1053\/j.gastro.2020.12.011","article-title":"Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study","volume":"160","author":"Emdin","year":"2021","journal-title":"Gastroenterol"},{"key":"2024110520090983600_goae097-B35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/hep.30623","article-title":"A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease","volume":"70","author":"Yang","year":"2019","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B36","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/liv.14616","article-title":"Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population","volume":"40","author":"Chen","year":"2020","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.mayocp.2020.08.020","article-title":"Sex differences in alcohol consumption and alcohol-associated liver disease","volume":"96","author":"Kezer","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2024110520090983600_goae097-B38","doi-asserted-by":"crossref","first-page":"112334","DOI":"10.1016\/j.exger.2023.112334","article-title":"Old age as a risk factor for liver diseases: Modern therapeutic approaches","volume":"184","author":"Georgieva","year":"2023","journal-title":"Exp Gerontology"},{"key":"2024110520090983600_goae097-B39","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.cgh.2020.11.038","article-title":"Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis","volume":"20","author":"Israelsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B40","doi-asserted-by":"crossref","first-page":"E273","DOI":"10.1016\/S0618-8278(19)30518-3","article-title":"Metabolic risk factors for advanced liver disease among alcohol risk users in the general population","volume":"70","author":"\u00c5berg","year":"2019","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B41","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/liv.14830","article-title":"Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: a population-based study","volume":"41","author":"Pose","year":"2021","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","article-title":"A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers","volume":"76","author":"Whitfield","year":"2022","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B43","doi-asserted-by":"crossref","first-page":"c1240","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies","volume":"340","author":"Hart","year":"2010","journal-title":"BMJ"},{"key":"2024110520090983600_goae097-B44","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.4103\/jfmpc.jfmpc_439_19","article-title":"Personal or family history of metabolic traits predispose to higher hepatotoxic effects of alcohol","volume":"8","author":"Bhadoria","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"2024110520090983600_goae097-B45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/liv.13958","article-title":"Positive familial history for metabolic traits predisposes to early and more severe alcoholic cirrhosis: a cross-sectional study","volume":"39","author":"Bhadoria","year":"2019","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B46","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1038\/s41467-023-43064-x","article-title":"Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease","volume":"14","author":"Ding","year":"2023","journal-title":"Nat Commun"},{"key":"2024110520090983600_goae097-B47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.gastha.2022.02.004","article-title":"Substance use disorder is associated with alcohol-associated liver disease in patients with alcohol use disorder","volume":"1","author":"Vannier","year":"2022","journal-title":"Gastro Hep Advances"},{"key":"2024110520090983600_goae097-B48","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/hep.510230513","article-title":"Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study","volume":"23","author":"Becker","year":"1996","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/acer.15220","article-title":"Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease","volume":"48","author":"Ting","year":"2024","journal-title":"Alcohol Clin Exp Res"},{"key":"2024110520090983600_goae097-B50","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatol"},{"key":"2024110520090983600_goae097-B51","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","article-title":"Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients","volume":"30","author":"Kim","year":"2010","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40001-022-00976-6","article-title":"Significance of Fib4 index as an indicator of alcoholic hepatotoxicity in health examinations among Japanese male workers: a cross-sectional and retrospectively longitudinal study","volume":"28","author":"Shinoda","year":"2023","journal-title":"Eur J Med Res"},{"key":"2024110520090983600_goae097-B54","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B55","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2023.06.030","article-title":"Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease","volume":"165","author":"Semmler","year":"2023","journal-title":"Gastroenterol"},{"key":"2024110520090983600_goae097-B56","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B57","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic HepatitisA randomized multicenter trial","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"key":"2024110520090983600_goae097-B58","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterol"},{"key":"2024110520090983600_goae097-B59","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.3748\/wjg.v12.i25.4020","article-title":"Predicting utility of a model for end stage liver disease in alcoholic liver disease","volume":"12","author":"Soultati","year":"2006","journal-title":"WJG"},{"key":"2024110520090983600_goae097-B60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jceh.2016.07.003","article-title":"Pharmacologic treatment of alcoholic hepatitis: examining outcomes based on disease severity stratification","volume":"6","author":"Owens","year":"2016","journal-title":"J Clin Exp Hepatol"},{"key":"2024110520090983600_goae097-B61","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.3748\/wjg.v12.i43.6909","article-title":"Current concepts and controversies in the treatment of alcoholic hepatitis","volume":"12","author":"Rongey","year":"2006","journal-title":"WJG"},{"key":"2024110520090983600_goae097-B62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4065\/mcp.2010.0281","article-title":"Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis","volume":"86","author":"Vaa","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2024110520090983600_goae097-B63","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/j.1572-0241.2008.02104.x","article-title":"A new scoring system for prognostic stratification of patients with alcoholic hepatitis","volume":"103","author":"Dominguez","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B64","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4254\/wjh.v15.i8.954","article-title":"Prognostic and diagnostic scoring models in acute alcohol-associated hepatitis: a review comparing the performance of different scoring systems","volume":"15","author":"Mitri","year":"2023","journal-title":"World J Hepatol"},{"key":"2024110520090983600_goae097-B65","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gut.2004.050781","article-title":"Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score","volume":"54","author":"Forrest","year":"2005","journal-title":"Gut"},{"key":"2024110520090983600_goae097-B66","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/gut.2006.099226","article-title":"The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids","volume":"56","author":"Forrest","year":"2007","journal-title":"Gut"},{"key":"2024110520090983600_goae097-B67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.14309\/ajg.0000000000001704","article-title":"The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: a global study","volume":"117","author":"Morales-Arr\u00e1ez","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B68","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cgh.2021.02.041","article-title":"Plasma-signature-model for end-stage liver disease score to predict survival in severe alcoholic hepatitis","volume":"20","author":"Fujiwara","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.alcohol.2006.01.003","article-title":"Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19","volume":"38","author":"Gonzalez-Quintela","year":"2006","journal-title":"Alcohol"},{"key":"2024110520090983600_goae097-B70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jceh.2022.07.246","article-title":"Emerging biomarkers in alcohol-associated hepatitis","volume":"13","author":"Im","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"2024110520090983600_goae097-B71","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000296","article-title":"A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: a multicenter plasma biomarker analysis","volume":"7","author":"Tornai","year":"2023","journal-title":"Hepatol Commun"},{"key":"2024110520090983600_goae097-B72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/alcalc\/agw059","article-title":"Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence","volume":"52","author":"Dunn","year":"2017","journal-title":"Alcohol Alcohol"},{"key":"2024110520090983600_goae097-B73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.15288\/jsa.2002.63.397","article-title":"The relationship between abstinence for one year following pretreatment assessment and alcohol use and other functioning at two years in individuals presenting for alcohol treatment","volume":"63","author":"Maisto","year":"2002","journal-title":"J Stud Alcohol"},{"key":"2024110520090983600_goae097-B74","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","article-title":"Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis","volume":"21","author":"Hofer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B75","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/hepr.12131","article-title":"Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis:a systematic review and meta-analysis","volume":"44","author":"Xie","year":"2014","journal-title":"Hepatol Res"},{"key":"2024110520090983600_goae097-B76","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/ADM.0000000000000760","article-title":"Can individuals with alcohol use disorder sustain non-abstinent recovery? non-abstinent outcomes 10 years after alcohol use disorder treatment","volume":"15","author":"Witkiewitz","year":"2021","journal-title":"J Addict Med"},{"key":"2024110520090983600_goae097-B77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3928\/02793695-20210819-05","article-title":"Factors affecting alcohol abstinence intentions of inpatients with alcohol use disorder","volume":"59","author":"Yang","year":"2021","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"2024110520090983600_goae097-B78","first-page":"11782218231162468","article-title":"Prior periods of abstinence among adults with an alcohol use disorder: a qualitative template analysis","volume":"17","author":"Ware","year":"2023","journal-title":"Subst Abuse"},{"key":"2024110520090983600_goae097-B79","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/add.15329","article-title":"Controlled drinking-non-abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-analysis and meta-regression","volume":"116","author":"Henssler","year":"2021","journal-title":"Addiction"},{"key":"2024110520090983600_goae097-B80","first-page":"CD012880","article-title":"Alcoholics anonymous and other 12-step programs for alcohol use disorder","volume":"3","author":"Kelly","year":"2020","journal-title":". CDSR"},{"key":"2024110520090983600_goae097-B81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/0253-7176.130960","article-title":"Evidence based psychosocial interventions in substance use","volume":"36","author":"Jhanjee","year":"2014","journal-title":"Indian J Psychol Med"},{"key":"2024110520090983600_goae097-B82","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1360-0443.2003.00438.x","article-title":"How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals","volume":"98","author":"Weisner","year":"2003","journal-title":"Addiction"},{"key":"2024110520090983600_goae097-B83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1037\/ccp0000250","article-title":"A meta-analysis of motivational interviewing process: Technical, relational, and conditional process models of change","volume":"86","author":"Magill","year":"2018","journal-title":"J Consult Clin Psychol"},{"key":"2024110520090983600_goae097-B84","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/add.12679","article-title":"Efficacy of motivational enhancement therapy on alcohol use disorders in patients with chronic hepatitis C: a randomized controlled trial","volume":"109","author":"Dieperink","year":"2014","journal-title":"Addiction"},{"key":"2024110520090983600_goae097-B85","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1037\/a0016830","article-title":"Toward a theory of motivational interviewing","volume":"64","author":"Miller","year":"2009","journal-title":"Am Psychol"},{"key":"2024110520090983600_goae097-B86","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/acer.13603","article-title":"Text messaging to reduce alcohol relapse in prelisting liver transplant candidates: a pilot feasibility study","volume":"42","author":"DeMartini","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"2024110520090983600_goae097-B87","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/acer.13771","article-title":"Using digital interventions to support individuals with alcohol use disorder and advanced liver disease: a bridge over troubled waters","volume":"42","author":"Suffoletto","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"2024110520090983600_goae097-B88","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/10503307.2018.1490973","article-title":"Do what you say and say what you are going to do: a preliminary meta-analysis of client change and sustain talk subtypes in motivational interviewing","volume":"29","author":"Magill","year":"2019","journal-title":"Psychother Res"},{"key":"2024110520090983600_goae097-B89","doi-asserted-by":"crossref","first-page":"68","DOI":"10.15288\/jsads.2014.75.68","article-title":"Psychosocial approaches to alcohol use disorders since 1940: a review","volume":"75","author":"McCrady","year":"2014","journal-title":"J Stud Alcohol Drugs Suppl"},{"key":"2024110520090983600_goae097-B90","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/alcalc\/agad051","article-title":"Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials","volume":"58","author":"Hemrage","year":"2023","journal-title":"Alcohol Alcohol"},{"key":"2024110520090983600_goae097-B91","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/alcalc\/agh163","article-title":"Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system","volume":"40","author":"Lee","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"2024110520090983600_goae097-B92","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/j.1530-0277.2002.tb02484.x","article-title":"Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors","volume":"26","author":"Harris","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"2024110520090983600_goae097-B93","first-page":"CD010487","article-title":"Disulfiram for alcohol use disorder","volume":"2018","author":"Pedersen","year":"2018","journal-title":"CDSR"},{"key":"2024110520090983600_goae097-B94","first-page":"8835647","article-title":"Disulfiram-induced acute liver injury","volume":"2020","author":"Ramer","year":"2020","journal-title":"Case Rep Hepatol"},{"key":"2024110520090983600_goae097-B95","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/add.13787","article-title":"The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial","volume":"112","author":"Hauser","year":"2017","journal-title":"Addiction"},{"key":"2024110520090983600_goae097-B96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-244X-11-41","article-title":"Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study","volume":"11","author":"Paparrigopoulos","year":"2011","journal-title":"BMC Psychiatry"},{"key":"2024110520090983600_goae097-B97","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.4088\/JCP.15m10053","article-title":"Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care","volume":"77","author":"Feinn","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"2024110520090983600_goae097-B98","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2024110520090983600_goae097-B99","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"2024110520090983600_goae097-B100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/jlts.1997.v3.ajlts0030206","article-title":"Alcoholic liver disease: natural history","volume":"3","author":"Diehl","year":"1997","journal-title":"Liver Transplantation"},{"key":"2024110520090983600_goae097-B101","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0016-5085(97)70142-2","article-title":"Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis","volume":"112","author":"Luca","year":"1997","journal-title":"Gastroenterol"},{"key":"2024110520090983600_goae097-B102","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(95)91685-7","article-title":"Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver","volume":"346","author":"Teli","year":"1995","journal-title":"Lancet"},{"key":"2024110520090983600_goae097-B103","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2468-1253(21)00191-6","article-title":"Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models","volume":"7","author":"DiMartini","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B104","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/hep.31235","article-title":"Integrated treatment of alcohol use disorder in patients with alcohol-associated liver disease: an evolving story","volume":"71","author":"Lucey","year":"2020","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cld.194","article-title":"Identification and management of alcohol dependence and withdrawal in alcoholic liver disease","volume":"2","author":"Glance","year":"2013","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2024110520090983600_goae097-B106","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.31042","article-title":"Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis","volume":"71","author":"Rogal","year":"2020","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B107","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/hep.30358","article-title":"Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease","volume":"70","author":"Caputo","year":"2019","journal-title":"Hepatol"},{"key":"2024110520090983600_goae097-B108","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjmed.2016.10.004","article-title":"Treatment of alcohol use disorder in patients with alcoholic liver disease","volume":"130","author":"Leggio","year":"2017","journal-title":"Am J Med"},{"key":"2024110520090983600_goae097-B109","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.psym.2019.12.004","article-title":"Confronting the crisis of comorbid alcohol use disorder and alcohol-related liver disease with a novel multidisciplinary clinic","volume":"61","author":"Winder","year":"2020","journal-title":"Psychosomatics"},{"key":"2024110520090983600_goae097-B110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CLD.0000000000000026","article-title":"Culture, stigma, and inequities creating barriers in alcohol use disorder management in alcohol-associated liver disease","volume":"21","author":"Sedarous","year":"2023","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2024110520090983600_goae097-B111","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG clinical guideline: alcohol-associated liver disease","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B112","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: management of alcohol-related liver disease","volume":"69","author":"Thursz","year":"2018","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B113","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B114","first-page":"1005","article-title":"Myokines are associated with progression, course and mortality in alcohol-associated liver disease","volume":"60","author":"Kaur","year":"2024","journal-title":"AP&T"},{"key":"2024110520090983600_goae097-B115","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1111\/liv.12798","article-title":"Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis","volume":"35","author":"Fialla","year":"2015","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B116","author":"AH Network","year":"2017"},{"key":"2024110520090983600_goae097-B117","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0168-8278(00)80219-6","article-title":"Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids","volume":"32","author":"Ta\u00efeb","year":"2000","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B118","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1053\/gast.1996.v110.pm8964410","article-title":"Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone","volume":"110","author":"Mathurin","year":"1996","journal-title":"Gastroenterol"},{"key":"2024110520090983600_goae097-B119","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1365-2036.2008.03685.x","article-title":"Systematic review: glucocorticosteroids for alcoholic hepatitis\u2013a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials","volume":"27","author":"Rambaldi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"2024110520090983600_goae097-B120","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"2024110520090983600_goae097-B121","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B122","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B123","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3109\/00365521.2011.587200","article-title":"Validation of prognostic scores for clinical use in patients with alcoholic hepatitis","volume":"46","author":"Sandahl","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"2024110520090983600_goae097-B124","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ajg.2016.539","article-title":"A day-4 lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis","volume":"112","author":"Garcia-Saenz-de-Sicilia","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.gastro.2015.06.020","article-title":"MELDing the Lille score to more accurately predict mortality in alcoholic hepatitis","volume":"149","author":"Kamath","year":"2015","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B126","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.3390\/jcm10112338","article-title":"Day-4 Lille score is a good prognostic factor and early predictor in assessing therapy response in patients with liver cirrhosis and severe alcoholic hepatitis","volume":"10","author":"Foncea","year":"2021","journal-title":"J Clin Med"},{"key":"2024110520090983600_goae097-B127","first-page":"478","article-title":"Practical concerns and controversies in the management of alcoholic hepatitis","volume":"12","author":"Im","year":"2016","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024110520090983600_goae097-B128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.1990.tb00482.x","article-title":"Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis","volume":"14","author":"Felver","year":"1990","journal-title":"Alcoholism Clin Exp Res"},{"key":"2024110520090983600_goae097-B129","first-page":"96","article-title":"Pentoxifylline may prevent renal impairment (hepatorenal-syndrome) in severe acute alcoholic hepatitis","volume":"14","author":"McHutchison","year":"1991","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B130","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B131","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B132","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/j.gastro.2004.09.089","article-title":"Anti-TNF therapy for severe acute alcoholic hepatitis: what went wrong?","volume":"127","author":"Blendis","year":"2004","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B133","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B134","first-page":"152","article-title":"Infections in severe alcoholic hepatitis","volume":"30","author":"Karakike","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"2024110520090983600_goae097-B135","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)","volume":"42","author":"Jim\u00e9nez","year":"2022","journal-title":"Liver Int"},{"key":"2024110520090983600_goae097-B136","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2023.4902","article-title":"Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial","volume":"329","author":"Louvet","year":"2023","journal-title":"JAMA"},{"key":"2024110520090983600_goae097-B137","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J Clin Invest"},{"key":"2024110520090983600_goae097-B138","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B139","doi-asserted-by":"crossref","first-page":"101074","DOI":"10.1016\/j.conctc.2023.101074","article-title":"Design of a multicenter randomized clinical trial for treatment of alcohol-associated hepatitis","volume":"32","author":"Tu","year":"2023","journal-title":"Contemp Clin Trials Commun"},{"key":"2024110520090983600_goae097-B140","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","article-title":"Randomized-controlled trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis","volume":"80","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B141","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3748\/wjg.v9.i1.125","article-title":"N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat","volume":"9","author":"Ozaras","year":"2003","journal-title":"WJG"},{"key":"2024110520090983600_goae097-B142","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"key":"2024110520090983600_goae097-B143","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"Stewart","year":"2007","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B144","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1665-2681(19)30863-4","article-title":"Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis","volume":"13","author":"Serv\u00edn-Caama\u00f1o","year":"2014","journal-title":"Ann Hepatol"},{"key":"2024110520090983600_goae097-B145","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"Higuera-de la Tijera","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2024110520090983600_goae097-B146","doi-asserted-by":"crossref","first-page":"100139","DOI":"10.1016\/j.jhepr.2020.100139","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Marot","year":"2020","journal-title":"JHEP Rep"},{"key":"2024110520090983600_goae097-B147","doi-asserted-by":"crossref","first-page":"369","DOI":"10.12998\/wjcc.v4.i11.369","article-title":"Case of severe alcoholic hepatitis treated with granulocytapheresis","volume":"4","author":"Watanabe","year":"2016","journal-title":"World J Clin Cases"},{"key":"2024110520090983600_goae097-B148","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1526-0968.2003.00012.x","article-title":"Adacolumn, an adsorptive carrier based granulocyte and monocyteapheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes","volume":"7","author":"Saniabadi","year":"2003","journal-title":"Ther Apher Dial"},{"key":"2024110520090983600_goae097-B149","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3350\/cmh.2020.0057","article-title":"Fecal microbiota transplantation in alcohol related liver diseases","volume":"26","author":"Shasthry","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"2024110520090983600_goae097-B150","first-page":"1","article-title":"Bovine colostrum in oral treatment of enterogenic endotoxaemia in rats","volume":"6","author":"D\u00f6hler","year":"2002","journal-title":"Crit Car"},{"key":"2024110520090983600_goae097-B151","first-page":"141","article-title":"Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I\/II clinical trial in NASH","volume":"5","author":"Mizrahi","year":"2012","journal-title":"J Inflamm Res"},{"key":"2024110520090983600_goae097-B152","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.14309\/ajg.0000000000002283","article-title":"The beneficial effects of lactobacillus GG therapy on liver and drinking assessments in patients with moderate alcohol-associated hepatitis","volume":"118","author":"Vatsalya","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B153","doi-asserted-by":"crossref","first-page":"60rv5","DOI":"10.1126\/scitranslmed.3001007","article-title":"The role of JNK proteins in metabolism","volume":"2","author":"Vallerie","year":"2010","journal-title":"Sci Transl Med"},{"key":"2024110520090983600_goae097-B154","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/hep.24599","article-title":"An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice","volume":"54","author":"Mandrekar","year":"2011","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jhep.2015.06.013","article-title":"Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice","volume":"63","author":"Iracheta-Vellve","year":"2015","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B156","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1189\/jlb.3AB1214-590R","article-title":"Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease","volume":"98","author":"Petrasek","year":"2015","journal-title":"J Leukoc Biol"},{"key":"2024110520090983600_goae097-B157","first-page":"8A","article-title":"Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial","volume":"68","author":"Mathurin","year":"2018","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B158","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.23167","article-title":"Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis","volume":"50","author":"Witek","year":"2009","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B159","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo","volume":"17","author":"Frenette","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B160","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.23837","article-title":"Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3","volume":"52","author":"Ki","year":"2010","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B161","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gutjnl-2018-317232","article-title":"Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice","volume":"68","author":"Hendrikx","year":"2019","journal-title":"Gut"},{"key":"2024110520090983600_goae097-B162","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B163","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14309\/ajg.0000000000002275","article-title":"Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis","volume":"119","author":"Hassanein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B164","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2018.05.012","article-title":"Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis","volume":"69","author":"Peeraphatdit","year":"2018","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B165","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/nu15061360","article-title":"Nutritional support for alcoholic liver disease","volume":"15","author":"Tadokoro","year":"2023","journal-title":"Nutrients"},{"key":"2024110520090983600_goae097-B166","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clnu.2006.01.018","article-title":"ESPEN guidelines on enteral nutrition: liver disease","volume":"25","author":"Plauth","year":"2006","journal-title":"Clin Nutr"},{"key":"2024110520090983600_goae097-B167","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/0148607195019004258","article-title":"Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment","volume":"19","author":"Mendenhall","year":"1995","journal-title":"J Parenter Enteral Nutr"},{"key":"2024110520090983600_goae097-B168","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","article-title":"ESPEN practical guideline: clinical nutrition in liver disease","volume":"39","author":"Bischoff","year":"2020","journal-title":"Clin Nutr"},{"key":"2024110520090983600_goae097-B169","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5604\/01.3001.0012.3132","article-title":"Adherence to appropriate nutrition in acute alcoholic hepatitis is low","volume":"17","author":"Trieu","year":"2018","journal-title":"Ann Hepatol"},{"key":"2024110520090983600_goae097-B170","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/alcalc\/agz036","article-title":"Alcoholic hepatitis: a review","volume":"54","author":"Hosseini","year":"2019","journal-title":"Alcohol Alcohol"},{"key":"2024110520090983600_goae097-B171","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2018.04.009","article-title":"Outcomes of early liver transplantation for patients with severe alcoholic hepatitis","volume":"155","author":"Lee","year":"2018","journal-title":". Gastroenterology"},{"key":"2024110520090983600_goae097-B172","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cgh.2020.11.024","article-title":"Patterns of alcohol use after early liver transplantation for alcoholic hepatitis","volume":"20","author":"Lee","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024110520090983600_goae097-B173","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.16143","article-title":"Liver transplantation for alcoholic hepatitis in the United States: excellent outcomes with profound temporal and geographic variation in frequency","volume":"21","author":"Cotter","year":"2021","journal-title":"Am J Transplant"},{"key":"2024110520090983600_goae097-B174","doi-asserted-by":"crossref","first-page":"503","DOI":"10.7326\/0003-4819-155-8-201110180-00006","article-title":"Decision making in liver transplant selection committees: a multicenter study","volume":"155","author":"Volk","year":"2011","journal-title":"Ann Intern Med"},{"key":"2024110520090983600_goae097-B175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/02791072.2021.1976887","article-title":"Predictors of relapse to alcohol and substance use: are there any differences between 3 and 12 months after inpatient treatment?","volume":"54","author":"Guliyev","year":"2022","journal-title":"J Psychoactive Drugs"},{"key":"2024110520090983600_goae097-B176","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.14309\/ajg.0000000000001901","article-title":"Early liver transplantation for severe alcohol-associated hepatitis and a history of prior liver decompensation","volume":"117","author":"Weinberg","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B177","doi-asserted-by":"crossref","first-page":"e14003","DOI":"10.1111\/ctr.14003","article-title":"Predicting harmful alcohol relapse after liver transplant: the HALT score","volume":"34","author":"Satapathy","year":"2020","journal-title":"Clin Transplant"},{"key":"2024110520090983600_goae097-B178","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/hep.30478","article-title":"Predicting low risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the sustained alcohol use post-liver transplant score","volume":"69","author":"Lee","year":"2019","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B179","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jamcollsurg.2017.12.044","article-title":"Liver transplantation for severe alcoholic hepatitis, updated lessons from the world's largest series","volume":"226","author":"Weeks","year":"2018","journal-title":"J Am Coll Surg"},{"key":"2024110520090983600_goae097-B180","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archinte.167.11.1183","article-title":"A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years","volume":"167","author":"De Gottardi","year":"2007","journal-title":"Arch Intern Med"},{"key":"2024110520090983600_goae097-B181","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"Mathurin","year":"2011","journal-title":"N Engl J Med"},{"key":"2024110520090983600_goae097-B182","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7182\/pit2013604","article-title":"The Alcohol Relapse Risk Assessment: a scoring system to predict the risk of relapse to any alcohol use after liver transplant","volume":"23","author":"Rodrigue","year":"2013","journal-title":"Prog Transpl"},{"key":"2024110520090983600_goae097-B183","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/ajt.17059","article-title":"Artificial intelligence to identify harmful alcohol use after early liver transplant for alcohol-associated hepatitis","volume":"22","author":"Lee","year":"2022","journal-title":"Am J Transplant"},{"key":"2024110520090983600_goae097-B184","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/apt.12427","article-title":"Determinants of long-term outcome in severe alcoholic hepatitis","volume":"38","author":"Potts","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2024110520090983600_goae097-B185","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0016-5085(19)33180-4","article-title":"Natural history of alcoholic hepatitis. 3. Histological changes","volume":"63","author":"Galambos","year":"1972","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B186","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0168-8278(87)80547-0","article-title":"Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease","volume":"4","author":"Marbet","year":"1987","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B187","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"2024110520090983600_goae097-B188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11901-016-0287-9","article-title":"Statins: the Panacea of Cirrhosis?","volume":"15","author":"Cabrera","year":"2016","journal-title":"Curr Hepatology Rep"},{"key":"2024110520090983600_goae097-B189","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis","volume":"112","author":"Kamal","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2024110520090983600_goae097-B190","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"2024110520090983600_goae097-B191","first-page":"485","article-title":"The use of statins in patients with cirrhosis","volume":"14","author":"Kaplan","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2024110520090983600_goae097-B192","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.3748\/wjg.v27.i28.4639","article-title":"Addition of statins to the standard treatment in patients with cirrhosis: safety and efficacy","volume":"27","author":"Mu\u00f1oz","year":"2021","journal-title":"WJG"},{"key":"2024110520090983600_goae097-B193","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B194","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S1047-2797(01)00223-X","article-title":"Coffee, caffeine, and the risk of liver cirrhosis","volume":"11","author":"Corrao","year":"2001","journal-title":"Ann Epidemiol"},{"key":"2024110520090983600_goae097-B195","doi-asserted-by":"crossref","first-page":"37488","DOI":"10.1038\/srep37488","article-title":"An updated dose-response meta-analysis of coffee consumption and liver cancer risk","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"2024110520090983600_goae097-B196","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3748\/wjg.v25.i8.888","article-title":"Current and future pharmacological therapies for managing cirrhosis and its complications","volume":"25","author":"Kockerling","year":"2019","journal-title":"WJG"},{"key":"2024110520090983600_goae097-B197","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jhep.2014.04.012","article-title":"Human serum albumin, systemic inflammation, and cirrhosis","volume":"61","author":"Arroyo","year":"2014","journal-title":"J Hepatol"},{"key":"2024110520090983600_goae097-B198","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.26338","article-title":"Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications","volume":"58","author":"Garcia-Martinez","year":"2013","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B199","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterol"},{"key":"2024110520090983600_goae097-B200","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","article-title":"Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials","volume":"55","author":"Bernardi","year":"2012","journal-title":"Hepatology"},{"key":"2024110520090983600_goae097-B201","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"2024110520090983600_goae097-B202","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1357-2725(99)00139-9","article-title":"S-Adenosylmethionine","volume":"32","author":"Lu","year":"2000","journal-title":"Int J Biochem Cell Biol"},{"key":"2024110520090983600_goae097-B203","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1111\/j.1530-0277.2011.01547.x","article-title":"S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial","volume":"35","author":"Medici","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"2024110520090983600_goae097-B204","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0168-8278(89)90083-4","article-title":"Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver","volume":"9","author":"Ferenci","year":"1989","journal-title":"J Hepatol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae097\/60431605\/goae097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goae097\/60431605\/goae097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:10:05Z","timestamp":1730837405000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goae097\/7876477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":204,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goae097","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2023,12,22]]},"article-number":"goae097"}}